IDXX — IDEXX Laboratories Inc
NASDAQ · Health Care · Health Care
- Latest Close
- $569.01
- 30-Day Move
- -19.2%
- Market Cap
- $45.3B
- Shares Outstanding
- 79,620,000
- P/E Ratio
- 42.8
- P/B Ratio
- 33.65
Analyst consensus: Buy · 22 analysts
IDEXX Laboratories Inc
A read-only Alphactor snapshot forIDEXX Laboratories Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$569.01
30-Day Move
-19.2%
Market Cap
$45.3B
Shares Outstanding
79,620,000
P/E Ratio
42.8
P/B Ratio
33.65
$569.01
-19.2%last 90 delayed daily bars
90D High
$726.41
90D Low
$548.51
Avg Volume
520,557
Gross margin is running at 61.8%, which gives a quick read on operating quality before you open the full model.
Net margin is 24.6%, useful for comparing IDXX against peers in Health Care.
IDXX is down 19.2% over the last 30 trading days shown on this page.
Latest operating income is $316M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$221.60
Rule of 40
34.7%
Latest Close
$569.01
30-Day Move
-19.2%
Market Cap
$45.3B
Shares Outstanding
79,620,000
P/E Ratio
42.8
P/B Ratio
33.65
ROE
66.0%
ROA
31.6%
Gross Margin
61.8%
Operating Margin
31.6%
Net Margin
24.6%
Debt / Equity
0.53
Current Ratio
1.23
Latest Revenue
$1.1B
Revenue
$1.1B
Gross Profit
$658M
Operating Income
$316M
Net Income
$248M
Gross Margin
6180.0%
Net Margin
2462.0%
Current Ratio
1.23
Debt / Equity
0.53
Fair Value
$221.60
Upside / Downside
-61.1%
Signal
Overvalued
Implied Growth
15.4%
DCF
$265.58
EPV
$138.96
EV/Rev
$260.27
Growth Assumption
8.5%
Discount Rate
8.4%
Terminal Growth
2.0%
Base FCF
$1.0B
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Moderate growth priced in
Altman Z
20.98
Safe
Piotroski
8
Strong (7-9)
Cash Conversion
1.12x
Rule of 40
34.7%
Acceptable
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $3.4B | $899M | $679M | $384M |
| 2023-12-31 | $3.7B | $1.1B | $845M | $773M |
| 2024-12-31 | $3.9B | $1.1B | $888M | $798M |
| 2025-12-31 | $4.3B | $1.4B | $1.1B | $1.0B |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Two Sigma Advisers
Filed 2025-05-15
--
--
Vanguard Group
Filed 2026-01-29
$6.7B
-0.2%
BlackRock
Filed 2024-05-10
$5.0B
--
Geode Capital Management
Filed 2026-02-09
$1.7B
+3.5%
Bank of New York Mellon
Filed 2026-02-10
$1.1B
-21.0%
Invesco
Filed 2026-02-19
$1.0B
+13.8%
4.05
Consensus
Buy—
—
—
22
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.